Skip to main content

Table 2 Treatment outcome analysis

From: Outcome and patterns of failure after postoperative intensity modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma

Factor

Associated level

Cox regression analysis hazard ratio (95% CI) (p-value)

  

LRRFS

DMFS

OS

Univariate analysis

    

Age (years)

>60

1.31 (0.42, 4.13) (0.64)

1.44 (0.24, 8.62) (0.69)

2.46 (0.65, 9.28) (0.18)

Sex

Male

0.92 (0.27, 3.07) (0.89)

0.75 (0.12, 4.48) (0.75)

1.81 (0.39, 8.44) (0.45)

KPS

≤70

1.20 (0.32, 4.44) (0.79)

0.94 (0.11, 8.46) (0.96)

0.74 (0.16, 3.42) (0.70)

T-classification

pT3-4

1.73 (0.56, 5.37) (0.34)

2.44 (0.41, 14.58) (0.33)

1.43 (0.44, 4.70) (0.55)

N-classification

pN2-3

4.71 (1.27, 17.45) (0.02)

114.6 (0.06, >1000) (0.22)

4.65 (1.23, 17.63) (0.02)

AJCC stage

IV

4.43 (0.97, 20.27) (0.05)

56.7 (0.04, >1000) (0.27)

4.13 (0.90, 19.10) (0.07)

Grading

G3

1.82 (0.58, 5.73) (0.31)

3.4 (0.57, 20.4) (0.18)

0.89 (0.24, 3.40) (0.87)

Resection margins

R1

0.65 (0.14, 2.98) (0.58)

0.78 (0.09, 6.96) (0.82)

1.73 (0.50, 5.93) (0.38)

ECE positive LN

yes

2.29 (0.74, 7.14) (0.15)

3.54 (0.58, 21.4) (0.17)

2.19 (0.66, 7.27) (0.20)

Chemotherapy*

yes

0.56 (0.18, 1.75) (0.32)

1.15 (0.19, 6.89) (0.88)

0.44 (0.13, 1.50) (0.20)

Flap reconstruction

yes

1.92 (0.58, 6.42) (0.29)

59.4 (0.04, >1000) (0.27)

2.48 (0.66, 9.35) (0.16)

Bilateral ND

yes

0.38 (0.10, 1.40) (0.15)

0.74 (0.12, 4.46) (0.75)

0.59 (0.17, 2.01) (0.40)

Gastrostomy tube

yes

1.68 (0.53, 5.30) (0.38)

1.70 (0.28, 10.17) (0.56)

1.03 (0.31, 3.38) (0.96)

Time OP to RT

> 6 weeks

0.59 (0.19, 1.89) (0.38)

0.73 (0.12, 4.37) (0.73)

0.68 (0.19, 2.35) (0.54)

Multivariate analysis

    

N-classification

pN2-3

4.71 (1.27, 17.45) (0.02)

n.a.

4.65 (1.23, 17.63) (0.02)

AJCC stage

IV

1.68 (0.15, 18.51) (0.67)

n.a.

1.53 (0.14, 16.94) (0.73)

  1. Abbreviations: LRRFS Locoregional recurrence-free survival, DMFS Distant metastasis-free survival, OS Overall survival, OP surgery, KPS Karnowsky performance score, ECE extracapsular extention, LN lymph node, n.a. not applicable, ND neck dissection, *including treatment with cetuximab.